Does comorbidity affect the benefit of intensive glycemic control in older patients with type 2 diabetes mellitus?

2008 ◽  
Vol 5 (2) ◽  
pp. 78-79 ◽  
Author(s):  
Christopher D Saudek ◽  
Rita R Kalyani
2010 ◽  
Vol 7 (6) ◽  
pp. 593-599 ◽  
Author(s):  
Christian S. Göbl ◽  
Werner Brannath ◽  
Latife Bozkurt ◽  
Ammon Handisurya ◽  
Christian Anderwald ◽  
...  

2012 ◽  
Vol 15 (3) ◽  
pp. 87-91
Author(s):  
Inna Igorevna Klefortova

Current article presents data on effects of intensive glycemic control with Diabeton MR on development and progression of diabeticnephropathy in patients with type 2 diabetes mellitus (T2DM), accumulated from ADVANCE (Action in Diabetes and Vascular Disease:Preterax and DiamicroN Modified Release Controlled Evaluation study). Influence of intensive therapy with Diabeton MR wasassessed in that study separately and in conjunction with active antihypertensive treatment with perindopril and indapamide.


2022 ◽  
Vol 12 (1) ◽  
pp. 67
Author(s):  
Nai-Ching Chen ◽  
Chien-Liang Chen ◽  
Feng-Chih Shen

Background: The adequate glycemic control and risk factors for hypoglycemia in older patients with dementia and type 2 diabetes mellitus (T2DM) remain unclear. This study aimed to analyze the status of glycemic control and determine the risk of hypoglycemia among these groups. Methods: A hospital admission record due to hypoglycemia through an emergency room with glucose supplementation in the Chang Gung Memorial Hospital was identified as a hypoglycemic event. Patients with dementia and T2DM without hypoglycemic events throughout the study period were defined as the control group. We gathered patients aged ≥65 years with a diagnosis of Alzheimer’s dementia (AD) and T2DM between 2001 and 2018 in the Chang Gung Research Database (CGRD). We extracted data included medication use, diagnoses, and biochemistry data from hospital records. Results: A total of 3877 older patients with dementia and T2DM with regular visits to the outpatient department were enrolled in this study. During the two-year follow-up period, 494 participants (12.7%) experienced hypoglycemia. Multivariable logistic multivariable regression models for hypoglycemic events showed that metformin had a protective effect (odds ratio (OR) = 0.75, p = 0.023), insulin had the highest risk (OR = 4.64, p < 0.001). Hemoglobin A1c (HbA1c) levels were not correlated with hypoglycemic events (OR = 0.95, p = 0.140). Patients with hypoglycemic episodes had a significantly higher proportion of ≥2 Charlson Comorbidity Index scores than those without hypoglycemic episodes (83.2% versus 56.4%, p < 0.001). Conclusions: Drug regimen affects hypoglycemic episodes but not HbA1c in older patients with dementia and T2DM. In addition, patients with more comorbidities experience an increased risk of hypoglycemia.


Sign in / Sign up

Export Citation Format

Share Document